Spots Global Cancer Trial Database for secondary progressive multiple sclerosis
Every month we try and update this database with for secondary progressive multiple sclerosis cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study Evaluating Mitoxantrone in Multiple Sclerosis | NCT00146159 | Secondary Progr... | Mitoxantrone | 18 Years - 55 Years | Wyeth is now a wholly owned subsidiary of Pfizer | |
| A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis. | NCT06372145 | Relapsing Multi... Secondary Progr... Progressive Rel... | Tolebrutinib Placebo Teriflunomide | 18 Years - | Sanofi | |
| Swiss Study of the Impact of Mayzent on SPMS Patients in a Long-term Non-interventional Study | NCT04895202 | Secondary Progr... | Siponimod | 18 Years - | Novartis | |
| A Study for Patients With Secondary Progressive Multiple Sclerosis | NCT00869726 | Secondary Progr... | dirucotide Placebo | 18 Years - 65 Years | Eli Lilly and Company | |
| Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND) | NCT01665144 | Secondary Progr... | BAF312 Placebo | 18 Years - 60 Years | Novartis | |
| Phase 1b Multiple Ascending Dose Study of Foralumab in Primary and Secondary Progressive MS | NCT05029609 | Primary Progres... Secondary Progr... Multiple Sclero... | Intranasal Fora... Placebo | 25 Years - 70 Years | Tiziana Life Sciences LTD | |
| Mayzent (Siponimod) Onboarding of Secondary Progressive Multiple Sclerosis (SPMS) Patients With MSGo | NCT05826028 | Secondary Progr... | 18 Years - | Novartis | ||
| Investigation of Simvastatin in Secondary Progressive Multiple Sclerosis | NCT00647348 | Secondary Progr... | Simvastatin Placebo | 18 Years - 65 Years | Imperial College London | |
| Comparison of Clinical Effects of Rituximab and Glatiramer Acetate in Secondary Progressive Multiple Sclerosis Patients | NCT03315923 | Secondary Progr... | Rituximab Glatiramer Acet... | 18 Years - 55 Years | Isfahan University of Medical Sciences | |
| Mayzent (Siponimod) Onboarding of Secondary Progressive Multiple Sclerosis (SPMS) Patients With MSGo | NCT05826028 | Secondary Progr... | 18 Years - | Novartis | ||
| A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis | NCT01416181 | Secondary Progr... | natalizumab Placebo | 18 Years - 58 Years | Biogen | |
| Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sclerosis (AMA-VACC) | NCT04792567 | Secondary Progr... | BAF312 Baseline diseas... BNT162 mRNA-1273 | 18 Years - 100 Years | Novartis | |
| Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis | NCT01684761 | Autoimmune Dise... Multiple Sclero... Secondary Progr... Disease Progres... Brain Atrophy | Tcelna Placebo | 18 Years - 60 Years | Opexa Therapeutics, Inc. | |
| Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) | NCT04411641 | Secondary Progr... | Tolebrutinib Placebo to matc... | 18 Years - 60 Years | Sanofi | |
| Open-Label Study to Evaluate the Efficacy of ECP in Secondary Progressive Multiple Sclerosis | NCT02296346 | Secondary Progr... | SoluMedrol Extracorporeal ... | 18 Years - 75 Years | University of Utah | |
| A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis | NCT01416181 | Secondary Progr... | natalizumab Placebo | 18 Years - 58 Years | Biogen | |
| Safety and Efficacy Study of MIS416 to Treat Secondary Progressive Multiple Sclerosis | NCT02228213 | Secondary Progr... | MIS416 Saline | 18 Years - 70 Years | Innate Immunotherapeutics | |
| A Study for Patients With Secondary Progressive Multiple Sclerosis | NCT00869726 | Secondary Progr... | dirucotide Placebo | 18 Years - 65 Years | Eli Lilly and Company | |
| Study Evaluating Mitoxantrone in Multiple Sclerosis | NCT00146159 | Secondary Progr... | Mitoxantrone | 18 Years - 55 Years | Wyeth is now a wholly owned subsidiary of Pfizer | |
| Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND) | NCT01665144 | Secondary Progr... | BAF312 Placebo | 18 Years - 60 Years | Novartis | |
| Long Term Special Drug Use-results Surveillance for Mayzent in SPMS Patients | NCT04593927 | Secondary Progr... | Mayzent | - 99 Years | Novartis | |
| Novel Imaging Markers in SPMS | NCT05357833 | Secondary Progr... Multiple Sclero... Multiple Sclero... | Ferumoxytol inf... Gadoteridol MRI Brain and C... | 35 Years - 65 Years | University of Utah | |
| Long Term Special Drug Use-results Surveillance for Mayzent in SPMS Patients | NCT04593927 | Secondary Progr... | Mayzent | - 99 Years | Novartis | |
| Dose Escalation Study to Evaluate the Penetration and Pharmacodynamic Effects of Baminercept in the Cerebrospinal Fluid (CSF)and Safety in Subjects With Secondary Progressive Multiple Sclerosis (SPMS) | NCT01181089 | Secondary Progr... | Placebo Baminercept | 18 Years - 57 Years | Biogen | |
| Open-Label Study to Evaluate the Efficacy of ECP in Secondary Progressive Multiple Sclerosis | NCT02296346 | Secondary Progr... | SoluMedrol Extracorporeal ... | 18 Years - 75 Years | University of Utah | |
| Mechanistic Studies of Phase III Trial With BAF312 in Secondary Progressive Multiple Sclerosis | NCT02330965 | Secondary Progr... | Blood Draw CSF collection ... | 18 Years - 60 Years | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sclerosis (AMA-VACC) | NCT04792567 | Secondary Progr... | BAF312 Baseline diseas... BNT162 mRNA-1273 | 18 Years - 100 Years | Novartis | |
| Impact of Mayzent on aSPMS Patients in a Long-term NIS in Italy | NCT05376579 | Active Secondar... | siponimod | 18 Years - 60 Years | Novartis | |
| Acceptance Based Telephone Support When Transitioning to SPMS | NCT04239664 | Secondary Progr... | Acceptance Base... | 18 Years - | University of Nottingham | |
| Dose Escalation Study to Evaluate the Penetration and Pharmacodynamic Effects of Baminercept in the Cerebrospinal Fluid (CSF)and Safety in Subjects With Secondary Progressive Multiple Sclerosis (SPMS) | NCT01181089 | Secondary Progr... | Placebo Baminercept | 18 Years - 57 Years | Biogen | |
| Open-Label Study to Evaluate the Efficacy of ECP in Secondary Progressive Multiple Sclerosis | NCT02296346 | Secondary Progr... | SoluMedrol Extracorporeal ... | 18 Years - 75 Years | University of Utah | |
| Dose Escalation Study to Evaluate the Penetration and Pharmacodynamic Effects of Baminercept in the Cerebrospinal Fluid (CSF)and Safety in Subjects With Secondary Progressive Multiple Sclerosis (SPMS) | NCT01181089 | Secondary Progr... | Placebo Baminercept | 18 Years - 57 Years | Biogen | |
| Efficacy and Safety of MBP8298 in Subjects With Secondary Progressive Multiple Sclerosis | NCT00468611 | Multiple Sclero... | MBP8298 | 18 Years - 65 Years | BioMS Technology Corp. | |
| MS-SMART: Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial | NCT01910259 | Secondary Progr... | Amiloride Riluzole Fluoxetine Placebo | 25 Years - 65 Years | University College, London | |
| Impact of Mayzent on aSPMS Patients in a Long-term NIS in Italy | NCT05376579 | Active Secondar... | siponimod | 18 Years - 60 Years | Novartis | |
| Novel Imaging Markers in SPMS | NCT05357833 | Secondary Progr... Multiple Sclero... Multiple Sclero... | Ferumoxytol inf... Gadoteridol MRI Brain and C... | 35 Years - 65 Years | University of Utah | |
| A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis. | NCT06372145 | Relapsing Multi... Secondary Progr... Progressive Rel... | Tolebrutinib Placebo Teriflunomide | 18 Years - | Sanofi | |
| Functional Electrical Stimulation for Individuals With Secondary Progressive Multiple Sclerosis | NCT01647321 | Secondary Progr... | Active cycling Passive cycling | 18 Years - 68 Years | Johns Hopkins University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
